// App-Quantinova.ai

e13031 : Real-world outcomes from the systemic use of CDK 4/6 inhibitors (CDKIs) in the management of ER positive (+) HER2 negative (-) metastatic breast cancer (mBC).

Researchers

Presenter

  • Karen DeSouza

Principal Investigators

  • Daniel Yeo

  • Maria Diossy

  • Sumbal Umar

  • Emma Gore

  • Sachin Trivedi

  • Anjana Anand

  • Srinivasan Madhusudan

  • Sarah Khan

Medical Centers

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Abemaciclib

  • Anastrozole

  • Fulvestrant

  • Palbociclib

  • Exemestane

  • Ribociclib

  • Letrozole

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved